Famos (Letrozole) is commonly used to manage specific types of hormone receptor-positive breast cancer in postmenopausal women, and is applied in clinical settings that involve various stages of the condition.

Therapeutic Role and Patient Benefit

This medication is relevant for addressing the risk of cancer recurrence in early-stage disease following initial treatment, and for providing control over active tumor proliferation in advanced or metastatic disease. Famos is typically applied in clinical contexts that require long-term risk management, such as the adjuvant setting, or when addressing established disease progression. It is also used as an extended adjuvant treatment for those who have completed five years of prior hormonal therapy. The core benefit supports the patient in managing disease activity and the potential for recurrence.

---

Quick Fact: Relief for Recurrence Risk Famos is applied in situations involving clinical risk factors for breast cancer recurrence, and may assist with mitigating this potential for recurrence, which contributes to easing the overall symptom load.

Who Can and Cannot Use Famos (Letrozole)?

Famos is approved for use only in postmenopausal women with a clearly established endocrine status. Its use is primarily restricted by reproductive status, age, and pre-existing medical conditions, as defined in regulatory labeling.

---

Contraindications and Prohibited Use

The medicine is contraindicated (must not be used) for several groups:

• Pregnancy and Lactation: Famos is absolutely contraindicated in women who are or may become pregnant, and while breastfeeding.
• Premenopausal Women: Use is prohibited for women who have not yet reached postmenopausal status.
• Hypersensitivity: Patients with a known allergy to Letrozole or any tablet ingredients.
• Hereditary Disorders: Patients with rare hereditary problems such as total lactase deficiency or galactose intolerance.

---

Restricted and Conditional Use

Certain populations require special medical consideration or monitoring:

• Organ Impairment: Patients with severe hepatic impairment (Child-Pugh C) or severe renal insufficiency (creatinine clearance less than 10 mL/ min) must be closely supervised, as safety data is limited.
• Pediatric Population: The medicine is not recommended for use in children and adolescents, as safety and efficacy have not been established.
• Osteoporosis Risk: Use is conditional and requires a formal assessment of Bone Mineral Density (BMD) before and during treatment for patients with a history or risk of fractures.

---

Primary Eligible Population

Famos is intended for adult and geriatric women with a confirmed postmenopausal status. No dose adjustment is typically required for older adults or those with mild to moderate renal or hepatic impairment.

Interactions with other medicines and products

The interaction profile for Famos (Letrozole) is structured around managing pharmacokinetic and pharmacodynamic constraints as defined in official regulatory labeling.

Interaction Restrictions and Avoidance

Interacting Substance/Class	Official Constraint	Regulatory Basis
Estrogen-Containing Therapies	Co-administration is to be avoided.	Diminishes pharmacological action (antagonism).
Tamoxifen/Other Anti-estrogens	Co-administration should be avoided.	Substantially decreases Famos plasma concentration.
Herbal Menopause Remedies	Co-administration should be avoided.	Potential to diminish pharmacological action.

Metabolic and Exposure Considerations

The metabolism of Famos is primarily mediated by the CYP2A6 and CYP3A4 enzymes. Famos has been identified as an in vitro inhibitor of CYP2A6 and a moderate inhibitor of CYP2C19. This creates a regulatory requirement for caution when Famos is co-administered with other medicinal products whose elimination is heavily dependent on these isoenzymes and which have a narrow therapeutic index. Specific drugs noted in regulatory documents requiring caution include Phenytoin and Clopidrogel. Famos may be taken with or without food, as no clinically significant interaction with food is documented.

Population-Specific Pharmacokinetic Note

Patients with severe hepatic impairment (Child-Pugh C) exhibit a defined population-specific pharmacokinetic effect. This condition results in approximately doubled systemic exposure (AUC) to Famos compared to healthy subjects, indicating substantially reduced clearance in this specific group.

Targeted Aromatase Enzyme Inhibition

Famos (Letrozole) initiates its action by highly selective and reversible inhibition of the Aromatase enzyme (CYP19) in peripheral tissues. This molecular action competitively blocks the enzyme from catalyzing the final step in the estrogen biosynthesis pathway. This specific mechanism results in a reduction of the body's primary source of circulating estrogen in the patient's physiology.

Systemic Estrogen Deprivation and Signaling Blockade

The consequence of enzyme inhibition is a significant systemic reduction in active estrogens, such as estradiol. This physiological change creates a state of estrogen deprivation throughout the body. By eliminating the circulating hormonal signal, the mechanism functionally prevents the growth and activity signals that rely on Estrogen Receptor (ER) signaling in sensitive cells, resulting in modulation of estrogen-dependent cellular activity.

Mechanistic Constraints and Pathway Dependency

The drug's activity is strictly limited by the biological makeup of the target tissues, meaning the mechanism does not affect cells that are Estrogen Receptor-negative (ER-). Furthermore, the efficacy is constrained by the possibility of the target cells activating alternative growth pathways (like EGFR/MAPK) that can bypass the need for estrogen, leading to a mechanistic boundary known as acquired resistance.

Famos (Letrozole) is administered solely via the oral route as a tablet. The standard regimen for all approved uses, including adjuvant and advanced disease, is a fixed dose of 2.5 mg taken once a day. This single daily dose is consistent for most patients and is generally taken without regard to meals. It is a procedural requirement that the tablet must be swallowed whole and not crushed or chewed to ensure proper delivery of the active ingredient.

The overall duration of use is defined by the specific treatment context. For the adjuvant setting, Famos is typically administered over a planned course of five years. In the context of advanced or metastatic disease, administration continues until clinical evidence of tumor progression is observed.

Standard prescribing information provides specific rules for special populations. The standard 2.5 mg dose requires no adjustment for older adults or for patients with mild-to-moderate hepatic impairment. However, in cases of severe hepatic impairment (Child-Pugh C), the administration schedule is modified to 2.5 mg every other day to allow for reduced metabolism. If a dose is missed, instructions advise taking it as soon as it is remembered unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped to prevent taking two doses concurrently.

Research Evidence: Overview of Studies for Famos (Letrozole)

Evidence for Use in Early-Stage Hormone Receptor-Positive Breast Cancer (Adjuvant Setting)

Large, carefully designed clinical trials, known as randomized controlled trials (RCTs), was studied for the agent was evaluated in studies focusing on the initial treatment phase for early-stage hormone receptor-positive breast cancer. These studies primarily included postmenopausal women and compared Famos to other hormonal agents included in the trial design. Researchers extensively monitored long-term outcomes, such as Disease-Free Survival (DFS), which is a measure of the time until the cancer returns, and overall survival.

Evidence for Extended Use After Initial Hormonal Therapy

Research has explored the effect of continuing Famos for an extended period in postmenopausal women who have completed five years of a prior hormonal treatment. The research explored long-term outcomes, specifically comparing the rates of Disease-Free Survival tracked in the Famos group versus the placebo group. The studies reported that during the treatment period, patterns observed in the data described a difference in event rates (DFS) between the Famos group and the placebo group.

Evidence for Use in Advanced or Metastatic Hormone Receptor-Positive Disease

Famos was evaluated in randomized trials focusing on the first hormonal treatment for postmenopausal women with hormone receptor-positive cancer that is locally advanced or has spread. Researchers monitored tumor size changes, Objective Response Rate (ORR), and the duration of time until the disease progressed (Time to Progression, TTP). The main comparative trials reported measurements of Objective Response Rate and the median duration of TTP for Famos versus the comparator agent.

Research Gaps and Areas of Uncertainty

It is important to understand where the current research evidence is limited or where scientific questions remain. Research so far indicates that certain groups of patients may have different outcomes than those with high expression, but subgroup findings are uncertain, and results apply only to the populations studied in the primary trials. Overall, research describes what has been observed so far, but research does not determine whether an individual will respond similarly to the group patterns described in the data.

Key Studies & References Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer (BIG 1-98) - ClinicalTrials.gov ID NCT00004205

Common questions about Famos (FAQ)

---

Q: What is Famos actually used for, besides the main things?

A: Famos (Letrozole) is officially approved for the treatment of certain types of hormone receptor-positive breast cancer in postmenopausal women. The approved indications, as defined in regulatory documents, include treatment in the adjuvant setting (initial treatment), extended adjuvant treatment, and treatment for advanced or metastatic disease. It is not approved for purposes other than these specific oncology uses.

---

Q: How long does Famos stay in your system?

A: According to official product information, the time it takes for Famos (Letrozole) to be eliminated from the body is relatively slow. The elimination half-life is described as approximately two days. This half-life is a factor in establishing the recommended once-daily administration.

---

Q: Does Famos cause weight gain or weight loss?

A: Official safety data from clinical trials indicates that weight gain is a common side effect of Famos (Letrozole), affecting up to 10% of patients. Weight loss is also documented in regulatory documents but is listed as a less common adverse reaction. Changes in weight are generally items noted on official labeling for informational purposes.

---

Q: What is the difference between Famos and [common similar drug name]?

A: Famos is officially classified as a nonsteroidal aromatase inhibitor. Its third-generation classification describes a potent and highly selective action that blocks the aromatase enzyme. This specific mechanism of hormonal suppression is what defines its pharmacological class and differentiates it from older or other types of hormonal agents.

---

Q: Does Famos make you feel tired or sleepy?

A: The official safety profile lists fatigue (a feeling of tiredness) as a very common side effect, affecting more than 10% of patients. Less commonly, dizziness and somnolence (sleepiness) are also documented. Official labeling advises that patients be aware of the possibility of these effects, particularly when performing activities that require alertness.

---

Q: Can Famos cause mood changes or anxiety?

A: Regulatory documents list depression as a common side effect of Famos (Letrozole), affecting between 1% and 10% of patients in trials. Other central nervous system effects, including anxiety, are also noted in official safety documentation but are considered a less common adverse reaction.

---

Q: Can Famos affect fertility in men or women?

A: Famos's official use is strictly limited to postmenopausal women and its mechanism involves significantly reducing estrogen. Due to the potential for embryo-fetal harm, official documents state that the medicine is contraindicated (must not be used) in women who are or may become pregnant.

---

Q: Does Famos affect liver or kidney function?

A: Official information states that the use of Famos requires specific consideration, including potential modification of the administration schedule, for patients with severe hepatic impairment (severe liver problems). Uncommonly, adverse reactions such as hepatitis (liver inflammation) and abnormal liver function tests are documented. Consideration is also advised for patients with severe kidney problems.

---

Q: Are there special warnings for people with heart conditions who take Famos?

A: Official documents advise that Famos has been associated with an increased risk of hypercholesterolemia (high cholesterol). Uncommon but documented effects include ischemic cardiac events (e.g., heart-related chest pain) and blood clots. Official documents indicate that patients with pre-existing heart conditions may require specific oversight.

---

Q: What happens if I stop taking Famos suddenly?

A: Famos is prescribed as part of a planned treatment course. Official patient information states that the decision to stop taking the medicine should be made in consultation with a healthcare provider, who can review the prescribed treatment course and provide appropriate guidance.

---

Q: How quickly does Famos start working?

A: Studies and official information indicate that Famos achieves a significant reduction of circulating estrogen levels—its primary mechanism of action—within 24 to 48 hours after the first dose. However, the medicine must be taken consistently, with steady-state drug levels typically reached within two to six weeks of continuous daily dosing.

---

Q: Can Famos be used for pain relief?

A: Famos is an anti-neoplastic agent that is officially approved solely for the treatment of certain types of hormone receptor-positive breast cancer. It is not approved or indicated for use as a general pain reliever for conditions outside of its approved indications.

---

Q: Is it okay to take Famos every day?

A: Yes, for all officially approved uses, the recommended regimen in regulatory documents is to take a single tablet once a day (daily). This consistent, single daily dose is the standard procedure for the entire duration of the planned treatment course.

---

Q: Are the side effects of Famos permanent?

A: Most common adverse reactions are generally expected to resolve once the medicine is discontinued. However, the mechanism of Famos significantly reduces estrogen, and one major long-term concern is the documented increased risk of osteoporosis and subsequent bone fractures, which represents a lasting change that may require monitoring.

---

Q: Does Famos affect blood pressure?

A: Yes, official safety documents from clinical trials list hypertension (high blood pressure) as a common side effect. This means it was observed in between 1% and 10% of patients taking Famos.

---

Q: What are the signs of an allergic reaction to Famos?

A: Signs of a serious allergic reaction described in patient information include rash, hives, itching, swelling of the face, mouth, tongue, or throat, or trouble breathing. These symptoms are considered serious and require prompt medical evaluation.

---

Q: Can you take Famos with other over-the-counter cold medicines?

A: Official documents do not list specific interactions with common over-the-counter cold medicines. However, Famos is metabolized by certain liver enzymes, and caution is advised when taking it with any medicine that has a narrow therapeutic index and is known to be metabolized by the same enzymes.

---

Q: Does Famos help with stress or nervousness?

A: Famos is not approved or indicated for the treatment of stress, nervousness, or any psychological disorder. Its only approved indications relate specifically to the hormonal treatment of certain types of breast cancer.

---

Q: What is the highest concentration of Famos available?

A: Famos (Letrozole) is available as a single, fixed-strength tablet formulation. The only approved concentration used for treatment is the 2.5 mg oral tablet.

---

Q: Is Famos an old or new drug?

A: Famos (Letrozole) was first approved by the U.S. FDA in 1998 for advanced breast cancer. Its long history of use and its classification as a third-generation aromatase inhibitor mean it is a well-established and extensively studied medicine in its class.

---

Q: Is it possible to become resistant to the effects of Famos over time?

A: Official documents acknowledge the concept of acquired resistance. The medicine's efficacy is limited by the possibility of the cancer cells activating alternative growth pathways that bypass the need for estrogen. In the advanced setting, treatment continues only until clinical evidence of tumor progression (resistance) is observed.

---

Q: Are there any specific genetic factors that influence how Famos works?

A: Studies and official information note that the metabolism of Famos is primarily carried out by the CYP2A6 and CYP3A4 enzymes in the liver. Differences in the activity of these enzymes between individuals due to genetics may influence the body's systemic exposure to the drug.

---

Q: What if I experience a rare side effect mentioned in the leaflet for Famos?

A: Official patient information suggests that individuals experiencing a rare or serious side effect should seek prompt medical evaluation. The proper steps for reporting an adverse event are generally defined in official documents. Having the medicine packaging and dosage information available can assist in medical evaluations.

---

Q: Does Famos cause dry mouth?

A: Official safety data lists dry mouth as an uncommon side effect (affecting less than 1% of patients) in the Gastrointestinal Disorders category. It is therefore not among the most common effects experienced by users.

Storage and Disposal Requirements

Famos (letrozole) tablets must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is a mandatory requirement to keep the medication in the original container, tightly closed, to protect it from excess heat and moisture, as stated in regulatory labeling. The product must always be stored out of the sight and reach of children.

Disposal Guidelines

Regulatory documents outline specific methods for disposing of unused or expired tablets. The recommended approach is to use a drug take-back program or an authorized collection site. Disposal should not occur via wastewater (flushing down the toilet). If household disposal is necessary, the medicine must be mixed with an undesirable substance, such as dirt or coffee grounds, placed in a sealed container, and then discarded in the trash to prevent accidental ingestion.